Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-specific CTLs in Stage IV Gastric Cancer
NCT02496273Phase 1Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of CEA-specific cytotoxic T lymphocytes in gastric cancer (GC), sponsored by Changzhou First People's Hospital. Primary endpoint: ELISPOT assays at 1 month. Started Jan 2016; status: active, not recruiting.
02
Drugs
CEA-specific cytotoxic T lymphocytes
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02496273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496273.